“Those of us who work with NK cells have no doubt that they are incredibly powerful at killing cancer cells,” said Veronika Bachanova, MD, PhD.
|Articles|January 1, 2002
Oncology NEWS International
- Oncology NEWS International Vol 11 No 1
- Volume 11
- Issue 1
Washington State Hikes Cigarette Tax
OLYMPIA, Washington-The overwhelming approval of a significant tax increase on cigarettes by the residents of Washington State has raised hopes among public health groups that other states will follow suit. By a margin of 65% to 35%,
Advertisement
OLYMPIA, WashingtonThe overwhelming approval of a significant tax increase on cigarettes by the residents of Washington State has raised hopes among public health groups that other states will follow suit. By a margin of 65% to 35%, Washington voters approved a state ballot initiative that raised the tax on cigarettes by 60 cents to $1.42 a pack. Washington’s excise tax on cigarettes is now the nation’s highest, followed by New York state at $1.11 a pack.
Articles in this issue
over 24 years ago
ODAC Sends Mixed Message on New Gliadel Wafer Indicationalmost 25 years ago
ONCC Certification Test Results Are Announcedalmost 25 years ago
Rituximab Ups Survival in Aggressive and Indolent NHLalmost 25 years ago
Topotecan Used in Aggressive Front-Line Therapy for SCLCalmost 25 years ago
Depsipeptide Shows Activity in T-Cell Lymphomaalmost 25 years ago
FDG-PET Useful in Newly Diagnosed and Recurrent NSCLCalmost 25 years ago
Adjuvant Anastrozole Superior to Tamoxifen in Huge ATAC Breast Cancer Trialalmost 25 years ago
ODAC Backs Adding HER-2 DNA Test to Herceptin Package Insertalmost 25 years ago
FDA and VA Plan Joint AIDS Studyalmost 25 years ago
Breast Conservation Increases With On-Site Radiation UnitAdvertisement
Related to this article
Tyler Wilhite, MD, discusses expanding a radiation oncology program to also utilize low-dose radiation therapy for benign diseases.
Allen Khodab, MD discussed how patients with larger prostates had reduced IPSS scores that normalized to the same level as those with normal-sized glands.
Jeffrey V. Matous, MD, explains why ramantamig’s MRD negativity rates are clinically significant in relapsed/refractory myeloma.
In the phase 2 RALLY-MF study, selcodebart produced a 55% major response rate among evaluable non–transfusion-dependent patients with myelofibrosis.
Experts in multiple myeloma discussed long-term MAIA and CEPHEUS trial data and their implications for daratumumab-based regimens in newly diagnosed disease.
Adjuvant radiotherapy significantly reduced meningioma recurrence or death vs observation in grade 2 atypical meningioma after complete surgical resection.
VIR-5500, a PSMA-targeted PRO-XTEN dual-masked T-cell engager, showed an 82% PSA50 response rate and 45% ORR at higher doses in heavily pretreated mCRPC.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Atezolizumab/Chemo for Stage III dMMR Colon Cancer
2
Building out a Radiopharmaceuticals Program in Oncology Care
3
Iberdomide Combination Doubles PFS vs SOC Therapy in R/R Multiple Myeloma
4
How Emory Became the First Adopter of the Liberty Endovascular Robotic System
5